Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immutep Ltd, discusses the rationale for a novel immunotherapy combination in patients with unresectable or metastatic melanoma.
Frederic Triebel, MD, PhD
Advertisement
Articles by Frederic Triebel, MD, PhD
Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immuntep Ltd, discusses a novel immunotherapy combination in melanoma.
Advertisement
Latest Updated Articles
Dr. Triebel on Novel Immunotherapy Combination in MelanomaPublished: November 30th 2018 | Updated:
Dr. Triebel on the Rationale for a Novel Immunotherapy Combination in MelanomaPublished: January 30th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
Hematology Experts Preview Key Abstracts to Watch at the 2026 Transplantation & Cellular Therapy Meetings
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5